专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050080239A1 Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease 审中-公开
标题翻译：葡萄糖-6-磷酸异构酶的自身抗体及其参与自身免疫性疾病
公开(公告)号：US20050080239A1
公开(公告)日：2005-04-14
申请号：US10630009
申请日：2003-07-29
申请人： Henrik Ditzel , Dennis Burton , Monica Schaller
发明人： Henrik Ditzel , Dennis Burton , Monica Schaller
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/55
摘要： It has been discovered that one of the causes of human rheumatoid arthritis is an autoimmune reaction to human glucose-6-phosphate isomerase. While human glucose-6-phosphate isomerase is a normal constituent of living tissue, and the underlying reasons for the autoimmune reaction are not understood, this discovery enables effective treatment of the disease, especially when the human immune reaction is the primary cause of the rheumatoid arthritis. The human antibody, anti-glucose-6-phosphate isomerase IgG, can be used to develop immunopolypeptides having binding capacity with the antigen. Antibodies and antibody fragments to the antiglucose-6-phosphate isomerase IgG, antisense oligonucleotides, conjugates of human GPI with cytotoxic agents, immobilized human GPI may be used to ameliorate or eliminate the immune reaction. The peptide, nucleotide products as well as methods of diagnosis and treatment are provided.
摘要翻译：已经发现人类类风湿性关节炎的一个原因是对人类葡萄糖-6-磷酸异构酶的自身免疫反应。虽然人类葡萄糖-6-磷酸异构酶是活组织的正常成分，并且自身免疫反应的根本原因尚不清楚，但是这种发现能够有效治疗疾病，特别是当人类免疫反应是类风湿病的主要原因时关节炎。人抗体，抗葡萄糖-6-磷酸异构酶IgG可用于开发与抗原具有结合能力的免疫多肽。可以使用抗葡萄糖-6-磷酸异构酶IgG，反义寡核苷酸，人GPI与细胞毒性剂的缀合物，固定化的人GPI的抗体和抗体片段来改善或消除免疫反应。提供了肽，核苷酸产物以及诊断和治疗方法。

2. 发明申请

US20050048070A1 Cancer-associated epitope 审中-公开
标题翻译：癌相关表位
公开(公告)号：US20050048070A1
公开(公告)日：2005-03-03
申请号：US10883020
申请日：2004-07-01
申请人： Henrik Ditzel , Jens Jensenius
发明人： Henrik Ditzel , Jens Jensenius
IPC分类号： G01N33/483 , A61K38/00 , A61K39/00 , A61K39/395 , A61K45/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/82 , C07K16/30 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50 , G01N33/574 , G01N33/58 , C12Q1/68 , C07H21/04
CPC分类号： C07K16/18 , A61K38/00 , A61K47/6843 , C07K14/47 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2319/00
摘要： The present invention provides a cancer-associated epitope comprised of two polypeptides, where the first polypeptide is from cytokeratin K8 and the second polypeptide is from cytokeratin K18. The cancer-associated epitope becomes exposed during malignant transformation, particularly during malignant transformation of colon, breast, ovarian, renal, lung and testicular tissues. Exposure of the cancer-associated epitope is by cleavage and removal of N-terminal peptides from cytokeratins K8 and K18. The invention also provides binding entities, including antibodies, where the affinity of such binding entities for the cancer-associated epitope can be as high as about 109 M−1 in cancer tissues, more than 100-fold higher than for cytokeratin K8/K18 complexes in normal tissues. The invention provides cancer-associated epitopes, binding entities, antibodies and methods of using such epitopes, binding entities and antibodies for detection and treatment of cancer.
摘要翻译：本发明提供由两个多肽组成的癌相关表位，其中第一个多肽来自细胞角蛋白K8，第二个多肽来自细胞角蛋白K18。癌症相关表位在恶性转化期间暴露，特别是在结肠，乳腺，卵巢，肾，肺和睾丸组织的恶性转化期间。癌症相关表位的暴露是通过从细胞角蛋白K8和K18中切割和去除N端肽。本发明还提供了结合实体，包括抗体，其中这种结合实体对癌症相关表位的亲和力在癌组织中可高达约10 -9 M -1，高于对于细胞角蛋白K8 / K18复合物在正常组织中。本发明提供癌症相关表位，结合实体，抗体和使用这些表位的方法，结合实体和抗体用于癌症的检测和治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式